CureVac Clause Samples

CureVac. Subject to CureVac’s obligations as set forth in paras (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of mRNA-Based vaccine and mRNA-Based antibody products targeting the SARS-CoV-2 Pathogen, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any mRNA-Based vaccine or mRNA-Based antibody targeting the SARS-CoV-2 Pathogen other than: (i) a COVID Product Developed and/or Commercialized under this Agreement, and (ii) the First-Gen COVID Vaccine Products, subject to Section 3.3.7. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party’s Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
View SourceView Similar (4)
CureVac. Subject to CureVac's obligations as set forth in items (ii) and (iii) of the Disclosure Letter, CureVac shall work exclusively with GSK on the Development, Manufacture and Commercialization of Products targeting a Collaboration Pathogens, and CureVac shall not, and shall procure that its Affiliates will not, develop, manufacture or commercialize, solely or with a Third Party, any prophylactic and/or therapeutic mRNA-Based vaccine or mRNA-Based antibody targeting a Collaboration Pathogen other than a Product Developed and/or Commercialized under this Agreement. This Section 2.3.2 and the covenants set forth herein shall not apply to activities of any Third Party (or such Third Party's Affiliates) that becomes an Affiliate of CureVac solely as a result of a Change of Control in CureVac, provided that such activities are performed without using the CureVac mRNA technology described in the CureVac Know-How or within the scope of specification of the CureVac Patent Rights.
View SourceView Similar (3)
CureVac. Overview: Founded in 2000 35, CureVac is a NASDAQ- listed36 biopharmaceutical company headquartered in Germany37. Its revenue in the same nine-month period increased by 304% from €10.6 million in 2019 to €42.8 million during the first nine months of 202038. 25 European Pharmaceutical Review, “AstraZeneca”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/organisations/astrazeneca/ 26 AstraZeneca, “Contact Information”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/investor-relations/annual-reports/annual-report-2016/contact-information.html 27 AstraZeneca, “FAQs”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/investor-relations/faqs.html 28 AstraZeneca, “What science can do - AstraZeneca Annual Report and Form 20-F Information 2020”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/content/dam/az/Investor_Relations/annual-report-2020/pdf/AstraZeneca_AR_2020.pdf 29 ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, “AstraZeneca COVID-19 Vaccine (AZD1222)”, January 27, 2021, ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-▇▇▇▇▇▇▇▇▇.pdf 30 European Medicines Agency, “Vaxzevria (previously COVID-19 Vaccine AstraZeneca)”, 31 Reuters, “AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine”, June 13, 2020, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/article/us-health-coronavirus-vaccines-idUSKBN23K0HW 32 ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, “The Serum Institute of India”, December 8, 2020, Fierce Pharma, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/special-report/top-10-manufacturers-fight-against-covid-19-serum-institute-india 33 ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇, “AstraZeneca hopes warmer storage needs for COVID-19 vaccine will be an advantage against mRNA competitors”, November 23, 2020, Fierce Pharma, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/manufacturing/astrazeneca-hopes-warmer-storage-needs-for-covid-19-vaccine-will-be-advantage-against 34 ▇▇▇▇▇▇ ▇▇▇▇▇, et al. Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology. medRxIV, 10 April 2021. Available online: ▇▇▇▇▇://▇▇▇.▇▇▇/10.1101/2021.04.08.21255103 35 CureVac, “History, How it all began”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/en/about-us/historie-rework/ 36 ▇▇▇▇▇▇ ▇▇▇▇▇▇, “▇▇▇▇▇▇▇ says well on track to request vaccine approval as planned”, May 5, 2021, Reuters, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/business/healthcare-pharmaceuticals/curevac-says-well-track-request-vaccine-approval-planned-2021-05-05/ 37 CureVac, “CVnCoV, CureVac’s mRNA-based vaccine candidate against COVID-19”, ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇/en/covid-19/#timel...
View SourceView Similar (2)

Related to CureVac

  • Commercial Operation (i) On or before December 31, 2021, Interconnection Customer must demonstrate commercial operation of all generating units. Demonstrating commercial operation includes achieving Initial Operation in accordance with Section 1.4 of Appendix 2 to this ISA and making commercial sales or use of energy, as well as, if applicable, obtaining capacity qualification in accordance with the requirements of the Reliability Assurance Agreement Among Load Serving Entities in the PJM Region.

  • Musculoskeletal Injury Prevention and Control The hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Elements Unsatisfactory Needs Improvement Proficient Exemplary IV-A-1. Reflective Practice Demonstrates limited reflection on practice and/or use of insights gained to improve practice. May reflect on the effectiveness of lessons/ units and interactions with students but not with colleagues and/or rarely uses insights to improve practice. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues, and uses insights gained to improve practice and student learning. Regularly reflects on the effectiveness of lessons, units, and interactions with students, both individually and with colleagues; and uses and shares with colleagues, insights gained to improve practice and student learning. Is able to model this element.

  • Synchronization, Commissioning and Commercial Operation 5.1.1 The SPG shall give PGVCL at least thirty (30) days’ advanced preliminary written notice and at least fifteen (15) days’ advanced final written notice, of the date on which it intends to synchronize the Solar Power Project to the Grid System. 5.1.2 Subject to Article 5.1.1, the Power Project may be synchronized by the SPG to the Grid System when it meets all the connection conditions prescribed in applicable Grid Code then in effect and otherwise meets all other Indian legal requirements for synchronization to the Grid System. 5.1.3 The synchronization equipment and all necessary arrangements / equipment including RTU for scheduling of power generated from the Project and transmission of data to the concerned authority as per applicable regulation shall be installed by the SPG at its generation facility of the Power Project at its own cost. The SPG shall synchronize its system with the Grid System only after the approval of synchronization scheme is granted by the head of the concerned substation/ and checking/verification is made by the concerned authorities of the PGVCL. 5.1.4 The SPG shall immediately after each synchronization/tripping of generator, inform the sub-station of the Grid System to which the Power Project is electrically connected in accordance with applicable Grid Code. In addition, the SPG will inject in-firm power to grid from time to time to carry out operational/ functional test prior to commercial operation. For avoidance of doubt, it is clarified that Synchronization / Connectivity of the Project with the grid shall not to be considered as Commissioning of the Project. 5.1.5 The SPG shall commission the Project within nine (9) Months from the Date of execution of this PPA. Declaration of COD shall be certified by the commissioning committee. 5.1.6 The Parties agree that for the purpose of commencement of the supply of electricity by SPG to PGVCL, liquidated damages for delay etc., the Scheduled Commissioning Date as defined in this Agreement shall be the relevant date.